Regeneron and Telix form $2.1B radiopharmaceutical alliance

Regeneron Pharmaceuticals (NASDAQ:REGN) and Telix Pharmaceuticals (NASDAQ:TLX) announced a landmark strategic collaboration on April 13, 2026, to co-develop and co-commercialize next-generation radiopharmaceutical therapies (RPTs).

The partnership marks a major expansion of Regeneron's oncology pipeline into the rapidly evolving field of targeted radiation.

The collaboration is structured on a 50/50 cost and profit-sharing basis for the global development and commercialization of new therapies.

Under the terms of the agreement, Telix will receive an upfront payment of $40 million for access to its proprietary RPT platform across four initial therapeutic programs.

Regeneron holds an option to expand the deal to include four additional programs, which would trigger further upfront payments.

The financial potential for Telix is significant; if the company opts out of co-funding for a specific program, it remains eligible for up to $535 million in development and commercial milestones per program, plus low double-digit royalties.

The aggregate milestone potential across the collaboration reaches $2.1 billion USD.

This alliance merges Regeneron’s world-class biologics discovery engine—including its VelocImmune® and bispecific antibody platforms—with Telix’s specialized expertise in radiopharmaceutical molecular design, global manufacturing, and supply chain logistics.

The primary focus will be on targeting multiple solid tumor types that have historically been difficult to treat with conventional immunotherapy alone.

In addition to therapeutic candidates, the partners will jointly develop radio-diagnostics (imaging agents).

These "companion" diagnostics will be used to support patient selection and real-time monitoring of treatment response, a core tenet of the precision oncology model.

Telix will lead the commercialization of these diagnostic assets, with Regeneron receiving a predetermined percentage of the profits.